Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Safer and More Effective: Health Yuan's Novel β-Lactamase Inhibitor Injection Ushers in an Upgrade for Infection Treatment
Published Time：
2025-01-02
Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Healthy Yuan") has launched China's first and the world's only novel β-lactamase inhibitor injection for combined use with meropenem. The launch of this innovative drug pipeline not only consolidates Healthy Yuan's leading position in the field of anti-infection, but also marks a comprehensive upgrade of its global R&D strategy, providing a revolutionary treatment option for addressing antibiotic resistance.
Meropenem, as a representative of carbapenem antibiotics, is known for its highly effective broad-spectrum antibacterial properties and is considered "one of the last lines of defense against antibiotics" . However, bacteria develop resistance to it through mechanisms such as producing β-lactamases, reducing its efficacy. The novel β-lactamase inhibitor developed by Healthy Yuan precisely breaks the bacteria's "defense mechanism," effectively restoring the antibacterial effect of meropenem and providing patients with safer and more effective treatment options.
01 Ultra-broad spectrum characteristics, allowing for widespread application in drug-resistant treatment
The novel β-lactamase inhibitor significantly enhances the antibacterial activity of β-lactam antibiotics by precisely inhibiting β-lactamases produced by drug-resistant bacteria. Its targeted mechanism can not only effectively inhibit Gram-negative bacteria (such as carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii), but also help address intractable clinical problems such as complicated lower respiratory tract infections (HAP/VAP) and complicated urinary tract infections (cUTI), providing a new treatment plan.
02 Reduced systemic side effects, optimized clinical safety
Unlike traditional systemic administration, this β-lactamase inhibitor is administered locally as an injection, avoiding excessive exposure of the drug throughout the body and significantly reducing the risk of common side effects (such as gastrointestinal discomfort and allergic reactions). This advantage provides a safer treatment option for patients with drug resistance, especially in complex situations involving the combined use of multiple antibiotics, optimizing clinical treatment outcomes.
03 Multiple indications covered, meeting broad clinical needs
Meropenem, as a carbapenem antibiotic, has a wide range of indications and can treat various infections, covering the needs of multiple clinical areas, including respiratory infections, intra-abdominal infections, urinary tract infections, central nervous system infections, and bloodstream infections such as sepsis. Among them, in Healthy Yuan's traditionally strong respiratory field, meropenem is very effective against hospital-acquired lower respiratory tract infections (HAP/VAP) . These infections are particularly common in hospital intensive care units, with an estimated annual incidence of 4.35 to 4.8 million cases.
Meanwhile, complicated urinary tract infections (cUTI) are currently the second most common infectious disease in the community, with complex cases particularly prevalent in diabetic populations (16%-35%) and existing treatment methods have certain limitations. The use of the novel β-lactamase inhibitor in combination with meropenem will provide new treatment options for these intractable infections.
Healthy Yuan has always regarded technological innovation as the core driving force for its development. The launch of this novel β-lactamase inhibitor represents a significant technological breakthrough for the company in the field of anti-infection and will help strengthen Healthy Yuan's layout and position in the respiratory field.
Currently, the company has a number of high-potential product pipelines in the field of anti-infection. The launch of the β-lactamase inhibitor not only reflects Healthy Yuan's responsibility in addressing global public health issues, but also lays a solid foundation for future development of other drug-resistant drugs.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.